Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Japanese Phase II Study of Rituximab plus FC Chemotherapy in Previously Untreated Chronic Lymphocytic Leukemia
jRCT2080222236Phase 2
- Sponsor
- Nippon Zenyaku Kogyo Co., Ltd.
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Nippon Zenyaku Kogyo Co., Ltd.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT2080222236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222236.